Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization
Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences
Colonization
0303 health sciences
Vaccination
Radboud University Medical Center
Intranasal vaccine
Antibodies, Bacterial
Pneumococcal Infections
3. Good health
Pneumococcal Vaccines
Mice
03 medical and health sciences
Laboratory Medicine - Radboud University Medical Center
Streptococcus pneumoniae
SDG 3 - Good Health and Well-being
Bacterial Proteins
Ecological Microbiology
Animals
Paediatrics - Radboud University Medical Center
Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences
Protein bodies
Immunity, Mucosal
Administration, Intranasal
DOI:
10.1016/j.vaccine.2021.10.006
Publication Date:
2021-10-25T13:43:10Z
AUTHORS (12)
ABSTRACT
Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a vaccine formulation. PBs can contain high concentrations of antigen, are stable and relatively resistant to proteases, release antigen slowly and are cost-effective to manufacture. Yet, the capacity of PBs to provoke immune responses and protection in the upper respiratory tract, a major entry route of respiratory pathogens, is largely unknown. In this study, we vaccinated mice intranasally with PBs comprising antigens from Streptococcus pneumoniae and evaluated the level of protection against nasopharyngeal colonization. PBs composed of the α-helical domain of pneumococcal surface protein A (PspAα) provided superior protection against colonization with S. pneumoniae compared to soluble PspAα. Immunization with soluble protein or PBs induced differences in antibody binding to pneumococci as well as a highly distinct antigen-specific nasal cytokine profile upon in vivo stimulation with inactivated S. pneumoniae. Moreover, immunization with PBs composed of conserved putative pneumococcal antigens reduced colonization by S. pneumoniae in mice, both as a single- and as a multi-antigen formulation. In conclusion, PBs represent a vaccine formulation that elicits strong mucosal immune responses and protection. The versatility of this platform offers opportunities for development of next-generation vaccine formulations.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....